Monitor serum CPK; weekly during use in all patients and more frequently in patients with recent prior or concomitant HMG-CoA reductase inhibitor therapy, renal insufficiency, or elevations in CPK.
Monitor renal function.
Monitor muscle pain or weakness, especially in the distal extremities.
Monitor signs and symptoms of peripheral neuropathy during use.
Repeat blood cultures and diagnostic evaluation for infectious foci; in patients with persistent or relapsing Staph. aurues bacteremia, endocarditis, or poor clinical response.